Evidence map›Paper›PMID 40604731›Full record

ArticleBMC public health2025

Sarcopenia index is associated with Alzheimer's disease, mild cognitive impairment and their mortality in Chinese adults aged 65 and older.

Chenxi Ren, Tingjun Hu, Jiehua Zhu, Heling Chu, Qihao Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenxi Ren *Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yi Shan Road, Shanghai, 200233, People's Republic of China.
Tingjun Hu *Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yi Shan Road, Shanghai, 200233, People's Republic of China.
Jiehua ZhuDepartment of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yi Shan Road, Shanghai, 200233, People's Republic of China.
Heling ChuDepartment of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yi Shan Road, Shanghai, 200233, People's Republic of China.
Qihao GuoDepartment of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yi Shan Road, Shanghai, 200233, People's Republic of China. qhguo@sjtu.edu.cn.

Funding

Shanghai Municipal Health Commission 202340173
6 · The paper itself

Abstract

backgroundSarcopenia index (SI) is a novel biomarker calculated as serum creatinine/cystatin C for estimating skeletal muscle mass. Higher SI indicates a higher degree of muscle loss and reduced muscle function. The study aimed to determine whether SI could potentially serve as a predictive marker for MCI (Mild Cognitive Impairment) and AD (Alzheimer's disease).

methodsA total of 176 participants ≥ 65 years of age were reviewed from the Department of Geriatrics at Shanghai Sixth People's Hospital between January 2019 and June 2021, and tracked their mortality between January 2019 and June 2021 were recorded. MCI and AD were respectively adapted from the criteria proposed by the Petersen RC and the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. SI was calculated by serum creatinine (mg/dL)/cystatin C (mg/L) ×100. Logistic regression was used to examine the association between SI and the prevalence of MCI and AD. Cox regression was employed to analyze the relationship between SI and mortality.

resultsAfter adjusting for potential confounders, increasing levels of SI indicated lower odds of MCI and AD, and showed more pronounced OR values (OR per 1-SD = 0.47, 95% CI: 0.27-0.83 in MCI; OR per 1-SD = 0.38, 95% CI: 0.20-0.71 in AD). The best SI cut-off value for AD was 76.2, and for MCI was 75.7. A total of 27 participants with MCI or AD (20.0%) died. The mortality according to the tertiles of the SI was 36.5%, 13.3% and 5.3% in low (< 76.9), medium (76.9-88.2) and high (> 88.2) groups, respectively (P for trend < 0.001). A higher SI had a lower risk of 3-year all-cause mortality after adjusting for potential confounders (HR per 1-SD = 0.40, 95% CI: 0.22-0.72). MCI and AD patients in the high SI group (SI > 88.2) exhibited the highest survival rates.

conclusionOur study demonstrated that SI was independently associated with both MCI and AD in individuals aged 65 and older, and it can serve as a predictor of mortality in these populations.

Indexed as

Alzheimer DiseaseCognitive DysfunctionSarcopeniaAgedAged, 80 and overBiomarkersChinaCreatinineCystatin CEast Asian PeopleFemaleHumansMaleBiomarkersCreatinineCystatin CAlzheimer’s diseaseMild cognitive impairmentMortalityOlderSarcopenia index

Identifiers

PMID40604731
PMCPMC12219112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.